Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
7Customers
3Debt Items
3Related Chains
Source-Backed Evidence Depth
NanoViricides, Inc. (NNVC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
13Total relationships
3Distinct source URLs
7High confidence
0.789Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
NanoViricides, Inc. Suppliers
Ticker
Name
Confidence
Evidence
D-BORAL-CAPITAL-LLC
D-BORAL-CAPITAL-LLC
92%
The Company entered into a Placement Agency Agreement with D. Boral Capital LLC (the “Placement Agent”), dated May 15, 2026, pursuant to which the Placement Agent acted as the exclusive placement age…
THERACOUR
THERACOUR
92%
Further, the Company has subcontracted nanomaterials research and development ("R&D") to TheraCour under the license agreement with TheraCour.
NanoViricides, Inc. Customers
Ticker
Name
Confidence
Evidence
THERACOUR
THERACOUR
90%
We will develop these drugs in part via subcontracts to TheraCour, the exclusive source for these nanomaterials.
Reciprocal relationship from SIGA graph: Reciprocal relationship from NNVC graph: public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also fo…
public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications lead…
EF-HUTTON-LLC
EF-HUTTON-LLC
62%
ion, NanoViricides will pay 15 % of net sales to TheraCour, as defined in the agreement. On March 27, 2023 the Company entered into a license agreement with KMPL wherein the Company granted to KMPL…
INDIA-KARVEER-MEDITECH-PRIVATE-LIMITED
INDIA-KARVEER-MEDITECH-PRIVATE-LIMITED
62%
public health importance, even for those viruses that do not exist today and cannot be predicted. The MoU has also formalized the process of development of drugs for unlicensed viral indications lead…
KARVEER-MEDITECH-PRIVATE-LIMITED
KARVEER-MEDITECH-PRIVATE-LIMITED
62%
ent, as well as Dengue virus drug development, which are at an early stage. The global Herpes Simplex Virus treatment market size was estimated at $2.47 billion in 2023 and is expected to grow at a c…
ONLYORPHANSCOTE-LLC
ONLYORPHANSCOTE-LLC
62%
ent, as well as Dengue virus drug development, which are at an early stage. The global Herpes Simplex Virus treatment market size was estimated at $2.47 billion in 2023 and is expected to grow at a c…
NanoViricides, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
NNVC-DEBT-11327
Warrants outstanding: 347222
90%
xbrl warrant detail from xbrl 2020-01-27.
NNVC-DEBT
Debt stack $4.7M
90%
Market cache reports total debt of $4.7M.
NNVC-DEBT-11328
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2024-06-30.
NanoViricides, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for NanoViricides, Inc..
NanoViricides, Inc. Ownership
Holder
Name
Confidence
Evidence
NNVC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 49 tracked holders.
